Sarkees v. E. I. DuPont de Nemours and Co., No. 20-3170 (2d Cir. 2021)
Annotate this Case
In 1974, when Sarkees was 19, he worked for Goodyear for seven months. Sarkees believed he was exposed to the chemical ortho-toluidine (OT). He took chemical samples and unloaded railroad tank cars, the majority of which contained OT, he drove a forklift to load Nailax2 (made with OT), and he manually cleaned Nailax reactors and packaged Nailax. While conducting many of these tasks, Sarkees recognized the smell of OT and experienced chemicals splashing on his skin. He often cleaned the inside of Nailax reactors, wearing “the same contaminated coveralls for the entire work shift.” Sarkees approximated that he cleaned the filters “more than 80 times,” inhaling a “strong chemical smell” and fumes without a respirator. A 2014 Department of Health and Human Services report states, “Epidemiological studies have demonstrated a causal relationship between exposure to o-toluidine and urinary-bladder cancer in humans.” Beginning in 1998, Sarkees participated in a bladder cancer screening program offered by Goodyear to former employees. In 2016, he was diagnosed with bladder cancer.
The district court dismissed his suit for negligence and strict products liability, after excluding expert testimony that OT was the specific cause of his cancer. The Second Circuit vacated. In excluding the expert’s opinion, the district court improperly relied on a state court evidence ruling instead of the applicable federal evidence rule. The evidence is admissible under Federal Rule 702 and “Daubert.”
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.